Literature DB >> 30283734

Reflections on the Management of Graves' Hyperthyroidism.

Chantal Daumerie1, Jacques Orgiazzi2.   

Abstract

Entities:  

Year:  2018        PMID： 30283734      PMCID： PMC6140606          DOI： 10.1159/000491585

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN： 2235-0640


× No keyword cloud information.
  3 in total

1.  Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves' disease: a retrospective observational study.

Authors:  Bijay Vaidya; Ailsa Wright; Joanna Shuttleworth; Mollie Donohoe; Roderick Warren; Antonia Brooke; Christian A Gericke; Obioha C Ukoumunne
Journal:  Clin Endocrinol (Oxf)       Date:  2014-05-19       Impact factor: 3.478

2.  Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery.

Authors:  Mirna Abraham-Nordling; Ove Törring; Bertil Hamberger; Göran Lundell; Leif Tallstedt; Jan Calissendorff; Göran Wallin
Journal:  Thyroid       Date:  2005-11       Impact factor: 6.568

3.  2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.

Authors:  Douglas S Ross; Henry B Burch; David S Cooper; M Carol Greenlee; Peter Laurberg; Ana Luiza Maia; Scott A Rivkees; Mary Samuels; Julie Ann Sosa; Marius N Stan; Martin A Walter
Journal:  Thyroid       Date:  2016-10       Impact factor: 6.568
  3 in total
  1 in total

1.  Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism.

Authors:  Ali Abbara; Sophie A Clarke; Rosalind Brewster; Alexia Simonnard; Pei Chia Eng; Maria Phylactou; Deborah Papadopoulou; Chioma Izzi-Engbeaya; Amir H Sam; Florian Wernig; Eliza Jonauskyte; Alexander N Comninos; Karim Meeran; Tom W Kelsey; Waljit S Dhillo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-12       Impact factor: 5.555
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.